WO2023177356A3 - Compounds and method for pkmyt1 inhibition - Google Patents

Compounds and method for pkmyt1 inhibition Download PDF

Info

Publication number
WO2023177356A3
WO2023177356A3 PCT/SG2023/050174 SG2023050174W WO2023177356A3 WO 2023177356 A3 WO2023177356 A3 WO 2023177356A3 SG 2023050174 W SG2023050174 W SG 2023050174W WO 2023177356 A3 WO2023177356 A3 WO 2023177356A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkmyt1
compounds
inhibition
threonine
tyrosine
Prior art date
Application number
PCT/SG2023/050174
Other languages
French (fr)
Other versions
WO2023177356A2 (en
Inventor
Toni Kline
Christine Taylor Brew
Stephen Harrison
Dimitri KHRAKOVSKY
Ojas A. Namjoshi
George L. Trainor
Eric Gordon
Original Assignee
Engine Biosciences Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engine Biosciences Pte. Ltd. filed Critical Engine Biosciences Pte. Ltd.
Publication of WO2023177356A2 publication Critical patent/WO2023177356A2/en
Publication of WO2023177356A3 publication Critical patent/WO2023177356A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The disclosure provides for compounds and methods for inhibiting protein kinase, membrane associate tyrosine/threonine 1 (PKMYT1).
PCT/SG2023/050174 2022-03-18 2023-03-17 Compounds and method for pkmyt1 inhibition WO2023177356A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263321376P 2022-03-18 2022-03-18
US63/321,376 2022-03-18

Publications (2)

Publication Number Publication Date
WO2023177356A2 WO2023177356A2 (en) 2023-09-21
WO2023177356A3 true WO2023177356A3 (en) 2023-11-02

Family

ID=88024576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2023/050174 WO2023177356A2 (en) 2022-03-18 2023-03-17 Compounds and method for pkmyt1 inhibition

Country Status (1)

Country Link
WO (1) WO2023177356A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024199388A1 (en) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 Compound acting as myt1 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034867A1 (en) * 1995-05-03 1996-11-07 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
CN108191857A (en) * 2017-01-24 2018-06-22 成都优赛丽医药科技有限公司 Pyrido [2,3-D] pyrimidines of 6- substitutions are as kinases inhibitor
WO2021202780A2 (en) * 2020-04-01 2021-10-07 Engine Biosciences Pte. Ltd. Methods and compositions for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034867A1 (en) * 1995-05-03 1996-11-07 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
CN108191857A (en) * 2017-01-24 2018-06-22 成都优赛丽医药科技有限公司 Pyrido [2,3-D] pyrimidines of 6- substitutions are as kinases inhibitor
WO2021202780A2 (en) * 2020-04-01 2021-10-07 Engine Biosciences Pte. Ltd. Methods and compositions for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTCZAK, C ET AL.: "Structure-activity relationships of 6-(2,6-dichlorophenyl)- 8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: Toward selective Abl inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 24, 23 October 2009 (2009-10-23), pages 6872 - 6876, XP029120863, [retrieved on 20231002], DOI: 10.1016/J.BMCL. 2009.10.08 5 *
KLUTCHKO, S. R ET AL.: "2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)- ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 17, 24 July 1998 (1998-07-24), pages 3276 - 3292, XP002191992, [retrieved on 20231002], DOI: 10.1021/JM9802259 *
PALMER, B.D ET AL.: "Structure-activity relationships for 2-anilino-6- phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 7, 1 April 2005 (2005-04-01), pages 1931 - 1935, XP004789411, [retrieved on 20231002], DOI: 10.1016/J.BMCL. 2005.01.07 9 *
ROHE, A ET AL.: "Evaluation of potential Myt1 kinase inhibitors by TR -FRET based binding assay", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, 12 June 2012 (2012-06-12), pages 41 - 48, XP028991149, [retrieved on 20231002], DOI: 10.1016/J.EJMECH. 2012.06.00 7 *

Also Published As

Publication number Publication date
WO2023177356A2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
TNSN07416A1 (en) Method of modulating stress-activated protein kinase system
AU2020330570A8 (en) Process of making CFTR modulators
MX2022010425A (en) Methods of treating estrogen receptor-associated diseases.
NO20050144L (en) Process for preparing substituted pyrimidines
MX2019005150A (en) Inhibitors of bruton's tyrosine kinase.
MX9709442A (en) Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions.
WO2002083064A3 (en) A method of treating cancer
AU7585598A (en) Raf kinase inhibitors
WO2023177356A3 (en) Compounds and method for pkmyt1 inhibition
WO2007041511A3 (en) Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2003084473A3 (en) Method of treating cancer
WO2006050109A3 (en) Novel kinase inhibitors
MXPA04004107A (en) Quinazoline derivatives for the treatment of abnormal cell growth.
AU2019279282A1 (en) Modified homoserine dehydrogenase and method for producing homoserine or l-amino acid derived from homoserine using the same
EP4397771A3 (en) Urine stabilization
EP1662197A3 (en) Metal reflector and method of producing the same
MX2021015620A (en) Cell for resisting transplant reaction and method.
WO2022159685A3 (en) Sars-cov-2 coronavirus antibodies and uses thereof
MX2023013912A (en) Methods for inhibiting ras.
PH12020500093A1 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
ZA202206670B (en) Anti-ly6g6d antibodies and methods of use
WO2020109776A3 (en) Biocatalytic techniques
WO2007022042A3 (en) Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
AU2020320233A8 (en) Anti-HER2/anti-4-1BB bispecific antibody and use thereof
EP4397977A3 (en) Systems and methods for preparing a sample and performing a real-time assay of the sample